New brachy product begins use

Article

The first patient has been treated with the Flexitron brachytherapy product, available from Nucletron and its developer, Isodose Control.

New brachy product begins use
The first patient has been treated with the Flexitron brachytherapy product, available from Nucletron and its developer, Isodose Control. The 40-channel afterloader was applied in the treatment of breast cancer at the Cancer Specialists of Oklahoma in Oklahoma City. Flexitron was recently integrated into Nucletron's offering of high dose rate brachytherapy afterloaders, applicators, and treatment planning solutions Sept. 1 when Nucletron and Isodose Control forged a partnership to serve the global brachytherapy marketplace. Nucletron is framing the newly introduced product as the next generation of afterloading platforms for cancer treatment. The brachytherapy product employs a 40-channel radiation delivery system with DICOM compatibility and includes dual radiation source capabilities and multiple isotope compatibility.

Recent Videos
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
What New Research Reveals About the Impact of AI and DBT Screening: An Interview with Manisha Bahl, MD
Can AI Assessment of Longitudinal MRI Scans Improve Prediction for Pediatric Glioma Recurrence?
A Closer Look at MRI-Guided Adaptive Radiotherapy for Monitoring and Treating Glioblastomas
Incorporating CT Colonography into Radiology Practice
What New Research Reveals About Computed Tomography and Radiation-Induced Cancer Risk
What New Interventional Radiology Research Reveals About Treatment for Breast Cancer Liver Metastases
New Mammography Studies Assess Image-Based AI Risk Models and Breast Arterial Calcification Detection
Can Deep Learning Provide a CT-Less Alternative for Attenuation Compensation with SPECT MPI?
Employing AI in Detecting Subdural Hematomas on Head CTs: An Interview with Jeremy Heit, MD, PhD
Related Content
© 2025 MJH Life Sciences

All rights reserved.